These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 2321450)

  • 1. Metastatic breast carcinoma in pleural fluid. Correlation of morphology with estrogen receptor activity and morphology of the primary carcinoma.
    Wiley EL; Von Roenn J
    Acta Cytol; 1990; 34(2):169-74. PubMed ID: 2321450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
    Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
    Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
    Ciampa A; Fanger G; Khan A; Rock KL; Xu B
    Cancer; 2004 Dec; 102(6):368-72. PubMed ID: 15558786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro clonogenic growth and metastatic potential of human operable breast cancer.
    Nomura Y; Tashiro H; Hisamatsu K
    Cancer Res; 1989 Oct; 49(19):5288-93. PubMed ID: 2766296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.
    Davidson B; Konstantinovsky S; Nielsen S; Dong HP; Berner A; Vyberg M; Reich R
    Clin Cancer Res; 2004 Nov; 10(21):7335-46. PubMed ID: 15534110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
    Keshgegian AA; Cnaan A
    Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
    de Candia P; Akram M; Benezra R; Brogi E
    Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Ciocca D; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; O'Sullivan J; Martino S; Osborne CK
    Clin Cancer Res; 1998 Jan; 4(1):7-12. PubMed ID: 9516946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma.
    Davidson B; Reich R; Lazarovici P; Ann Flørenes V; Nielsen S; Nesland JM
    Breast Cancer Res Treat; 2004 Jan; 83(2):119-28. PubMed ID: 14997042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions.
    Sears D; Hajdu SI
    Acta Cytol; 1987; 31(2):85-97. PubMed ID: 3469856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers.
    Kurbel S
    Med Hypotheses; 2005; 64(6):1182-7. PubMed ID: 15823713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
    J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Estrogen and progesterone receptors of primary breast carcinoma and their axillary lymph node metastases--immunohistochemical investigations of routine formalin-fixed paraffin-embedded tissue].
    Schulze MH; Buchmann J
    Zentralbl Gynakol; 2000; 122(2):92-5. PubMed ID: 10721188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphologic and clinical aspects of estrogen receptors in carcinoma of the breast.
    Kern WH
    Surg Gynecol Obstet; 1979 Feb; 148(2):240-2. PubMed ID: 217114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen and progesterone receptors in neoplastic cells of metastatic pleural effusion of breast carcinoma before and after tamoxifen therapy. Correlation with the clinical response.
    Di Lorenzo D; Zaniboni A; Simoncini E; Marpicati P; Montini E; Alghisi A; Gorni F; Marini G
    Chemioterapia; 1986 Aug; 5(4):232-6. PubMed ID: 3769044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity.
    Bhargava V; Kell DL; van de Rijn M; Warnke RA
    Am J Pathol; 1994 Sep; 145(3):535-40. PubMed ID: 8080038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancers--a Southwest Oncology Group study.
    Fabian CJ; Kimler BF; McKittrick R; Park CH; Lin F; Krishnan L; Jewell WR; Osborne CK; Martino S; Hutchins LF
    Cancer Res; 1994 Oct; 54(20):5357-62. PubMed ID: 7923165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.